High-fat diet leads to same intestinal inflammation as a virus – UCLA Newsroom

FINDINGS

A new study by scientists at UCLA found that when mice eat a high-fat diet, the cells in their small intestines respond the same way they do to a viral infection, turning up production of certain immune molecules and causing inflammation throughout the body. The scientists also found that feeding the mice tomatoes containing a protein similar to that in HDL, or good cholesterol, along with the generic cholesterol drug Ezetimibe, reversed the inflammation.

The results could lead to new types of drugs, targeting the intestinal cells, to reduce peoples risk of heart attacks and strokes, or to treat other conditions linked to inflammation, including cancer and inflammatory bowel disease.

Researchers already knew that prolonged obesity can cause inflammation of the liver and fat tissues, and that this inflammation contributes to the development of diabetes and heart disease. Studies have also shown that higher levels of high-density lipoprotein, or HDL, cholesterol, reduces a persons risk of heart disease.

The UCLA research team, led by Alan Fogelman, chair of the department of medicine at the David Geffen School of Medicine at UCLA,previously developed genetically engineered tomatoes that contained 6F, a protein resembling the main protein in high-density lipoprotein. In early experiments on 6F, they found that the compound was active in the small intestines of mice, and that it reduced inflammation. But exactly how it did this was unclear.

The scientists fed either a standard chow or a high-fat, high-cholesterol Western diet to mice that were especially prone to developing clogged arteries. They also treated some of the mice with either 6F, in the form of a tomato concentrate containing the protein, Ezetimibe, or both. After two weeks, cells from the small intestines of the mice were collected and blood samples were taken. The researchers measured cholesterol levels as well as the levels of inflammatory and immune molecules in both the intestines and throughout the body.

The findings shed light on the molecular details of how high-fat diets cause inflammation in the body, by making the intestines activate the pathway normally triggered by a virus. This suggests that blocking this immune reaction as 6F and Ezetimibe do may treat inflammatory diseases and decrease peoples risk of heart attack and stroke.

The authors of the study are all faculty and researchers at UCLA, affiliated with the Department of Medicine; Department of Molecular and Medical Pharmacology; Department of Human Genetics; Department of Microbiology, Immunology & Molecular Genetics; Department of Pathology and Laboratory Medicine; Department of Obstetrics and Gynecology; Semel Institute for Neuroscience and Human Behavior; and Department of Molecular, Cell and Developmental Biology. The first author is Pallavi Mukherjee; Fogelman is the senior author.

The studywas published June 7, 2017, in the Journal of Lipid Research.

The study was funded by the United States Public Health Service (2P01 HL-30568) and the Castera, Laubisch, and Milt Grey funds at UCLA.

Alan Fogelman, Mohamad Navab and Srinivasa Reddy are principals in Bruin Pharma, which is working to commercialize apoA-I mimetics, including the 6F peptide studied in this paper; Fogelman is additionally an officer of the company.

Go here to see the original:
High-fat diet leads to same intestinal inflammation as a virus - UCLA Newsroom

Cell Medica boosts manufacturing capacity in cell therapy deal – BioPharma Dive

Dive Brief:

Even more than traditional drug development, manufacturing is a crucial step in the development of complex therapeutics like cell therapies. As the field evolves, it will likely be a difference maker between success and setback. Such focus on production and logistics can be see in the attention paid to the processes set up by the more advanced CAR-T developers like Kite Pharma, Novartis and Juno Therapeutics.

With this deal, Cell Medica has seized on an opportunity to gain access to an existing GMP facility, taking a short cut to support further development and potential commercialization of the WT1-TCR therapy. More cell therapy products might also be produced at the site in the future, Cell Medica said.

Catapult Therapy TCR was created by CGT Catapult, UCL Business and Imperial Innovations the technology transfer arms of University College London and Imperial College, London in order to develop the WT1-TCR cell therapy.

By acquiring Catapult Therapy TCR, Cell Medica can also integrate WT1-TCR cell therapy into its Dominant TCR platform technology. This has potential to improve efficacy, Cell Medica believes, and to expand use of the therapeutic from its existing focus on blood cancers to hard-to-treat solid tumors such as mesothelioma and ovarian cancer.

Cell Medica recently upped its financial firepower,closinga 60 million ($75.9 million) Series C investor round in March 2017 to further develop its cell-based cancer immunotherapies.

Read more here:
Cell Medica boosts manufacturing capacity in cell therapy deal - BioPharma Dive

Langer-backed Sigilon sets sail with $23M and new ‘living’ cell therapy tech – Endpoints News

While Flagship Pioneering was unwrapping a huge $120 million round for Rubius this morning, the busy venture group also launched a biotech on a mission to create a new type of encapsulated cell therapy.

Turning to two scientific founders MITs Daniel Anderson and the prolific Robert Langer the discovery group at Flagship has been working on permeable biomaterials that are designed to implant cells in tissue to deliver proteins in a sustained fashion, without triggering fibrosis.

Paul Wotton, CEO, Sigilon

Researchers have been refining this tech in Flagships VentureLabs for the past two years, and now they are pursuing it at Sigilon Therapeutics with a $23.5 million A round.

Imagine the potential of a living therapeutic that could be implanted in the body and manufacture and release therapeutic proteins at steady levels for long periods of time, avoiding the critical limitations of intermittent infusion required with current therapies, said CEO Paul Wotton.

Flagship has pulled together another veteran team for this new player.

Wotton ran Ocata until it was bought out by Astellas. This rest of the team includes chief technology officer David Peritt, a Pfizer vet, and chief strategyofficer and head of operations Devyn Smith, who was previously head of operations and strategy for the medicinal sciences division of worldwide R&D at Pfizer. James Watson, chief business officer of Sigilon Therapeutics, previously served as CBO at Alvine Pharmaceuticals.

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Link:
Langer-backed Sigilon sets sail with $23M and new 'living' cell therapy tech - Endpoints News

Mayo Clinic Ventures funds new cancer-fighting cell, gene therapy … – Post-Bulletin

SAN FRANCISCO, Calif. Mayo Clinic Ventures has partnered with a California-based company to make cancer-fighting gene therapies available to the public.

Vineti, a pioneering cell and gene therapy software and analytics company, announced Tuesday that it had completed its initial round of funding raising $13.75 million aimed at delivering "the first cloud-based software solution to improve patient access, accelerate life-saving treatment delivery, and promote safety and regulatory compliance for individualized cell therapies."

The funding was provided by Mayo Clinic Ventures, GE Ventures, DFJ and LifeForce Capital. It's just the 15th company that Mayo Clinic Ventures has backed since it was formed, according to Andy Danielson, vice chairman of Mayo Clinic Ventures.

"One thing with Vineti that we liked is that we have a commitment to cell and gene therapies at Mayo," Danielson told TechCrunch.com. "Vineti will make the gene and cell therapy production process more efficient and as a result, less costly. It's all part of the equation of making these therapies more affordable and opening them up to a greater number of people."

The targeted cancer therapy under development by Vineti is part of a thriving field that conducted more than 800 clinical trials in 2016 while investing nearly $6 billion. It's all aimed at positively impacting the oncology field, the largest market in medicine that's expected to grow to $165 billion by 2021.

The first two cell therapies are expected to hit the market later this year.

Vineti touts its plans as one that "integrates logistics, manufacturing and clinical data to improve product performance overall and enable faster, broader access for patients."

"Physicians, medical researchers and pharmaceutical companies are working together to develop successful therapies, transitioning from a one-size-fits-all model to individualized treatments for each patient," said Amy DuRoss, CEO at Vineti. "Now, the process for creating and delivering these treatments can be as innovative as the therapies themselves. We are developing the Vineti platform to help these treatments reach the patients who need them the most, and are confident the partnership between our advances technologies and leading medical research will deliver better outcomes across the globe."

Excerpt from:
Mayo Clinic Ventures funds new cancer-fighting cell, gene therapy ... - Post-Bulletin

Stem cell therapy relying on patient’s own unhealthy heart may be dangerous – Genetic Literacy Project

A new study at Tel Aviv University shows that stem cell therapy, one of the few treatments available to patients with severe and end-stage heart failure, can actually harm them unless it is done differently.

We concluded that stem cells used in cardiac therapy should be drawn from healthy donors or be better genetically engineered for the patient, said lead researcher Jonathan Leor of the universitys Sackler Faculty of Medicine and Sheba Medical Center.

Doctors use tissue or adult stem cells to replace damaged tissue, which encourages regeneration of blood vessel cells and new heart muscle tissue. But cardiac stem cells from a diseased heart can lead to a toxic interaction via a molecular pathway between the heart and the immune system, the study found.

We found that, contrary to popular belief, tissue stem cells derived from sick hearts do not contribute to heart healing after injury, Leor said. Furthermore, we found that these cells are affected by the inflammatory environment and develop inflammatory properties. The affected stem cells may even exacerbate damage to the already diseased heart muscle.

[Read the fully study here (behind paywall)]

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:Study says some stem cells dangerous for heart patients

The rest is here:
Stem cell therapy relying on patient's own unhealthy heart may be dangerous - Genetic Literacy Project

Study says some stem cells dangerous for heart patients – The Times of Israel

A new study at Tel Aviv University shows that stem cell therapy, one of the few treatments available to patients with severe and end-stage heart failure, can actually harm them unless it is done differently.

We concluded that stem cells used in cardiac therapy should be drawn from healthy donors or be better genetically engineered for the patient, said lead researcher Jonathan Leor of the universitys Sackler Faculty of Medicine and Sheba Medical Center.

Doctors use tissue or adult stem cells to replace damaged tissue, which encourages regeneration of blood vessel cells and new heart muscle tissue. But cardiac stem cells from a diseased heart can lead to a toxic interaction via a molecular pathway between the heart and the immune system, the study found.

We found that, contrary to popular belief, tissue stem cells derived from sick hearts do not contribute to heart healing after injury, Leor said. Furthermore, we found that these cells are affected by the inflammatory environment and develop inflammatory properties. The affected stem cells may even exacerbate damage to the already diseased heart muscle.

The findings could suggest a way to make stem cell therapy safer for heart disease patients. The treatment is often a last resort, apart from getting a transplant.

Researchers discovered a molecular pathway involved in the toxic interaction while studying stem cells in mice with heart disease. By deleting the gene that makes the pathway, the cells ability to regenerate healthy tissue can be restored, they found.

The researchers are now testing a gene editing technique to delete the problem gene.

We hope our engineered stem cells will be resistant to the negative effects of the immune system, Leor said.

The study was conducted by TAUs Dr. Nili Naftali-Shani and published in the journal Circulation.

Read more:
Study says some stem cells dangerous for heart patients - The Times of Israel

GE and the Mayo Clinic back software to bring cancer-fighting gene … – TechCrunch

Behind the incredible process of developing targeted gene therapies to fight diseases like cancer lies an incredibly mundane problem that prevents these treatments from getting to patients paperwork and procedures.

While $5.7 billion was invested in companies developing cellular and genetic therapies, and with 800 clinical trials initiated worldwide and the first two CAR-T cell therapies expected to launch into market later this year, businesses still saythe ability to get these treatments to patients is limited by paperwork, supply chain management, and last mile delivery.

So GE (through its GE Ventures arm), the Mayo Clinic (through Mayo Clinic Ventures) and the venture investment firm DFJ have invested $13.75 million to back Vineti a software platform the companies are billing as a solution to gene therapys supply chain problem.

Its only the sixth company to have actually been built by GEs internal business team and spun out by the conglomerates venture arm.

According to company co-founder and former GE Ventures managing director Amy DuRoss, the process for developing and managing gene therapies is critical to the success of the treatment.

Amy DuRoss, chief executive at Vineti

To that end, Vinetis software tracks logistics, manufacturing and clinical data to improve treatments and drive down the cost of these therapies (which are mainly only accessible to those people with the very best health plans).

The startups technology was actually born out of necessity (always the mother of invention) and came from conversations that GE was having with a large, undisclosed customer.

A pharma company that is a regular client of GE Healthcare said we are solving late stage cancer and we want to take this commercial but we have not got the technology that can ensure that we can scale out these technologies in the commercial phase, DuRoss told me.

GEs healthcare business then took the problem to the companys venture investment and new business arm and began the development process of building a business.

In addition to DuRoss, who has been a luminary in the life sciences field since she helped with the push to get stem cell research approved in California; Vineti has a murderers row of leading healthcare talent.

Chief strategy officer Heidi Hagen, was the former SVP of Operations for cell immunotherapy pioneer Dendreon; chief technology officer Razmik Abnous was the chief technology officer at the healthcare data management juggernaut Documentum; and Malek Faham, the companys chief science officer, literally worked on some of the foundational science for gene therapies.

While the companys technology could have applications for a number of different treatments, and be used for several kinds of therapies, the focus, for now, is on cancer.

Cancer is a bullseye, says DuRoss. It is arguably the biggest cause of human suffering [and] there are treatments already in phase three, that if brought to market effectively could mark a turning point in medicines battle against the deadly disease, she said.

We see an opportunity as data accrues to the system over time for a use case in predicting therapy based on outcome data but were not making these claims today, said DuRoss.

Mayo Ventures had been working with GE for two years from the initial concept to the close of this new round of financing for Vineti. Its one of only 15 companies that the Clinic has backed since the formation of Mayo Clinic Ventures, and according to Andy Danielsen, the vice chair of Mayo Clinic Ventures.

One thing with Vineti that we liked is that we have a commitment to cell and gene therapies at Mayo, said Danielsen, so the interests were aligned. Vineti will make the gene and cell therapy production process more efficient and as a result, less costly. Its all part of the equation of making these therapies more affordable and opening them up to a greater number of people.

Therapy supply chain

External ordering pages

Product tracking

Therapy scheduling

Identity verification

The rest is here:
GE and the Mayo Clinic back software to bring cancer-fighting gene ... - TechCrunch

Here’s Why US Stem Cell Inc (OTCMKTS:USRM) Shares Just … – The Oracle Dispatch

US Stem Cell Inc (OTCMKTS:USRM) had been looking promising, in gear, and in control of one of the more promising narratives bouncing around on the OTC in recent months following the successful extrication from some legal issues a few months ago. However, that narrative was powerfully dependent on one critical piece of the puzzle a fact which became clear in the stocks reaction to the companys press release on Monday morning of this week.

Couched in the clothes of a message about expansion in its stem cell treatment centers and clinics, the company dropped the bomb that it is giving up on its strategy of obtaining Regenerative Medicine Advanced Therapy (RMAT) Designation from the FDA for its Myocell product. We got an update from the company a couple months ago that it was awaiting a decision from the FDA on this through its MARVEL trial. One can imagine that the market takes Mondays press release as an indication that the FDA provided the company with a sense that there was no point in staying with the application process, for one reason or another.

US Stem Cell Inc (OTCMKTS:USRM) bills itself as a company committed to the development of effective cell technologies to treat a variety of diseases and injuries. By harnessing the bodys own healing potential, we may be able to reverse damaged tissue to normal function.

U.S. Stem Cells discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.

USRM is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases. It is our belief that the unique qualities within the various cell types make them more advantageous to treat a particular disease.

According to company materials, US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

You can find outwhen $USRM stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

As noted above, USRM shares tanked on Monday in response to the companys indication that hope for an RMAT designation from the FDA was ill-placed. Weve witnessed just shy of -50% ripped out of prices for shareholders of the name during the trailing week. Whats more, the listing has seen interest climb, with an increase in recent trading volume of 63% beyond what we have been seeing over the larger time frame.

As also noted, the company did include an announcement of a strategic expansion of its treatment clinic approach. Specifically, the company announced an aggressive plan to expand an additional 12 stem cell treatment centers and clinics in the US.

In the release, the company further clarified its new reality once again: To be clear, U.S. Stem Cell will focus on our revenue generating programs that are treating patients NOWwhich have successfully helped over 7000 patients thus far. Our company was founded in 1999 and has completed more clinical treatments (for both humans and animals) than any other regenerative medicine company in the world. In addition to our efforts at US Stem Cell Training and VetBiologics, our focus will be expanding and opening additional clinics throughout the U.S. to offer these cutting-edge technologies to more patients.

At this time, carrying a capital value in the market of $13.7M, USRM has a store ($619K) of cash on the books, which is balanced by about $3.3M in total current liabilities. One should also note that debt has been growing over recent quarters. USRM is pulling in trailing 12-month revenues of $3.5M. In addition, the company is seeing major top line growth, with y/y quarterly revenues growing at 62.5%. We will update the story again soon as further details emerge. For continuing coverage on shares of $USRM stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

Read the original post:
Here's Why US Stem Cell Inc (OTCMKTS:USRM) Shares Just ... - The Oracle Dispatch

3D-Printed Human Embryonic Stem Cells Created for First Time

Researchers have developed a 3D printer that prints human embryonic stem cells.

Imagine if you could take living cells, load them into a printer, and squirt out a 3D tissue that could develop into a kidney or a heart. Scientists are one step closer to that reality, now that they have developed the first printer for embryonic human stem cells.

In a new study, researchers from Heriot-Watt University in Edinburgh have created a cell printer that spits out living embryonic stem cells. The printer was capable of printing uniform-size droplets of cells gently enough to keep the cells alive and maintain their ability to develop into different cell types. The new printing method could be used to make 3D human tissues for testing new drugs, grow organs, or ultimately print cells directly inside the body.

Human embryonic stem cells (hESCs) are obtained from human embryos and can develop into any cell type in an adult person, from brain tissue to muscle to bone. This attribute makes them ideal for use in regenerative medicine repairing, replacing and regenerating damaged cells, tissues or organs. [Stem Cells: 5 Fascinating Findings]

In a lab dish, hESCs can be placed in a solution that contains the biological cues that tell the cells to develop into specific tissue types, a process called differentiation. The process starts with the cells forming what are called "embryoid bodies." Cell printers offer a means of producing embryoid bodies of a defined size and shape.

The new 3D cell printer used compressed air to squirt out "bio-inks" containing cells and nutrient-rich fluid.

In the new study, the cell printer was made from a modified CNC machine (a computer-controlled machining tool) outfitted with two "bio-ink" dispensers: one containing stem cells in a nutrient-rich soup called cell medium and another containing just the medium. These embryonic stem cells were dispensed through computer-operated valves, while a microscope mounted to the printer provided a close-up view of what was being printed.

The two inks were dispensed in layers, one on top of the other to create cell droplets of varying concentration. The smallest droplets were only two nanoliters, containing roughly five cells.

The cells were printed onto a dish containing many small wells. The dish was then flipped over so the droplets now hung from them, allowing the stem cells to form clumps inside each well. (The printer lays down the cells in precisely sized droplets and in a certain pattern that is optimal for differentiation.)

Tests revealed that more than 95 percent of the cells were still alive 24 hours after being printed, suggesting they had not been killed by the printing process. More than 89 percent of the cells were still alive three days later, and also tested positive for a marker of their pluripotency their potential to develop into different cell types.

Biomedical engineer Utkan Demirci, of Harvard University Medical School and Brigham and Women's Hospital, has done pioneering work in printing cells, and thinks the new study is taking it in an exciting direction. "This technology could be really good for high-throughput drug testing," Demirci told LiveScience. One can build mini-tissues from the bottom up, using a repeatable, reliable method, he said. Building whole organs is the long-term goal, Demirci said, though he cautioned that it "may be quite far from where we are today."

Others have created printers for other types of cells. Demirci and colleagues made one that printed embryonic stem cells from mice. Others have printed a kind of human stem cells from connective tissues, which aren't able to develop into as many cell types as embryonic stem cells. The current study is the first to print embryonic stem cells from humans, researchers report in the Feb. 5 issue of the journal Biofabrication.

Editor's Note:This article was corrected at 2:45 p.m. Eastern Time, April 3 to correct the researchers' affiliation.

Follow LiveScience on Twitter @livescience. We're also on Facebook& Google+.

Original post:
3D-Printed Human Embryonic Stem Cells Created for First Time

Cell Medica Acquires Catapult Therapy for Lead WT1-TCR T-Cell … – Genetic Engineering & Biotechnology News (blog)

Cell Medica is buying Catapult Therapy TCR and the firm's gene-modified WT1-TCR (Wilms' tumor 1 proteinT-cell receptor) T-cell therapy candidate. The treatment is currently in Phase I/II development for the potential treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Catapult Therapy TCR is a special purpose vehicle established by The Cell and Gene Therapy Catapult (CGT Catapult), UCL Business (UCLB), and Imperial lnnovations to develop the WT1-TCR T-cell therapy, which was originally discovered by researchers at University College London (UCL) and Imperial College London. Financial details of the acquisition were not disclosed.

Cell Medical says it plans to apply its Dominant TCR platform to generate a more effective WT1-TCR product that could also feasibly be used to treat challenging solid tumors, including mesothelioma and ovarian cancer. The firm acquired the Dominant TCR technology from UCLB in 2016.

London, U.K.-based Cell Medica and CGT Catapult will carry out further development of the next generation of T cells, and manufacturing process, at the latters recently built large-scale cell and gene therapy manufacturing center at the Stevenage BioScience Catalyst, U.K.A Phase I/II study with the enhanced Dominant WT1-TCR candidate is projected to start during late 2018.

The acquisition of the WT1-TCR cell therapy leverages the investment we made in 2016 for exclusive rights to the Dominant TCR technology, said Gregg Sando, CEO of Cell Medica. Our objective is to show how we can enhance any existing TCR cell therapy with the Dominant TCR technology to create a more effective treatment for patients with solid tumors who otherwise have a very poor prognosis. We are also looking forward to an important collaboration with CGT Catapult to initiate manufacturing at the Stevenage GMP facility, where we will work together on scale-up strategies for commercial production.

With support from Innovate UK, CGT Catapult operates as a Centre of Excellence for Innovation to help drive growth of the U.K.s cell and gene therapy industry and translate early-stage research into new therapies. "We are pleased that Cell Medica has acquired the WT1 T-cell immunotherapy," added Keith Thompson, CEO at CGT Catapult. "With their complementary technologies, they will take over the development of this exciting new therapy. The next-generation product developed in our manufacturing center underlines our ability to support the localization of cell manufacturing processes in the U.K.

Cell Medica is exploiting its proprietary activated T-cell chimeric antigen receptor (CAR) and engineered TCR platforms to develop cellular immunotherapies targeting cancer. Lead product CMD-003 (baltaleucel-T) is being evaluated in the Phase II CITADEL study as a treatment for advanced lymphomas associated with the oncogenic Epstein-Barr virus.In March, Cell Medica raised 60 million (approximately $76 million) in a Series C investment roundto support development of its pipeline.

The firm has an ongoing CAR development partnership with Baylor College of Medicine and is working with UCL to leverage the Dominant TCR technology. Cell Medicas acquisition of Delenex Therapeutics in mid-2016 gave the firm an antibody fragment platform for use in developing anticancer CAR-NKT (natural killer T cells) products, and additional immune cell engineering expertise.

Originally posted here:
Cell Medica Acquires Catapult Therapy for Lead WT1-TCR T-Cell ... - Genetic Engineering & Biotechnology News (blog)